Potent and Selective Deubiquitinating Enzyme Inhibitor
Technology
University of Delaware and the National Institutes of Health are currently seeking licensing opportunities for an invention pertaining to inhibitors that target the USP1-UAF1 deubiquitinase (DUB) complex. The FDA approval and the commercial success of VelcadeĀ®, a small molecule inhibitor of human proteasome, has established the ubiquitin-proteasome system (UPS) as a valid target for the treatment of cancer. Since small-molecule proteasome inhibitors in general suffer from a narrow therapeutic index and acquired resistance, a promising alternative to proteasome inhibition is to target the enzymes upstream of proteasome-mediated protein degradation, i.e. the ubiquitin conjugation and deconjugation, to generate more specific, less toxic therapeutic agents. The investigators of this invention have developed small molecules that target the USP1-UAF1 DUB complex that acts upstream of proteasome and has been implicated in the human DNA damage responses. These compounds represent the most potent and selective DUB inhibitors reported to date. Additionally, the inhibitors act synergistically with cisplatin, a widely prescribed anti-cancer drug, to overcome chemoresistance and reduce toxic side effects. Results suggest that the USP1-UAF1 inhibitors may improve both the efficacy and potency of the commonly prescribed chemotherapeutic agents that are known to induce DNA damage.
Applications
- Potential commercial applications of this invention can be in the treatment of cancer, overcoming chemoresistance to platinum anticancer drugs and other DNA-damaging anticancer drugs, and the preparation of pharmaceutical compositions.